Wealth Enhancement Advisory Services, LLC Protagonist Therapeutics, Inc Transaction History
Wealth Enhancement Advisory Services, LLC
- $65.4 Billion
- Q4 2025
A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 3,554 shares of PTGX stock, worth $300,703. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,554
Previous 3,511
1.22%
Holding current value
$300,703
Previous $233,000
28.76%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PTGX
# of Institutions
297Shares Held
66.8MCall Options Held
139KPut Options Held
40.7K-
Farallon Capital Management LLC San Francisco, CA6.2MShares$524 Million1.78% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$487 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$487 Million5.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.26MShares$360 Million0.0% of portfolio
-
State Street Corp Boston, MA3.17MShares$268 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $4.15B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...